Research often lumps young adults into the 18–65 age group, ignoring crucial developmental and physiological differences. This leads to misguided treatment decisions and missed chances to improve long-term outcomes for conditions like #IBD.
Read more: https://t.co/pD8ZsCb4x9
Colorectal cancer is the #1 cause of cancer death in men under 50. This is why #45istheNew50.
Our team at #BIDMC_GI is here to help schedule your screening.
📞 617-754-8888
💻 https://t.co/xxbsUDgFjD
#ColorectalCancerAwarenessMonth
Stay proactive about your health! If you have IBD, you're at a higher risk of colorectal cancer. Talk to our team today about getting your screening.
📞 617-754-8888
💻 https://t.co/xxbsUDgFjD
#ColorectalCancerAwarenessMonth
Common scenario in IBD clinic answered by @sidbarritt4
💎 Isolated HBcAb pts on anti-TNF agents are considered low risk and do not necessarily require HBV prophylaxis
@DCharabaty @IBDConference #AIBD2024
One of the best summary slides at #AIBD2024 by Dr. Marla Dubinsky:
Specific scenarios for positioning IBD therapy 💉💊
And as Dr. @MLongMD said: “JAKs for joints, ILs for skin”
@IBDConference @DrCoreySiegel @MRegueiroMD@CCYANetwork
Thank you for a wonderful conference 🔥🔥
Excellent UP treatment algorithm; consider use of topical/rectal tacrolimus before moving on to other advanced therapy. Consider etrasimod given UP subgroup in clinical trials. #AIBD2024 @IBDConference
#AIBD2024 clinical trials stopped early due to significant improvement on tacrolimus for refractory UP. Significant clinical and endoscopic improvement seen. @IBDConference @mchiorean4
Live from #AIBD2024: Some non-invasive IBD biomarkers are less reliable in ulcerative proctitis including intestinal ultrasound and fecal calprotectin @IBDConference @mchiorean4
UP risk factors for progression; it is important to explain to patients they have a risk for extension of disease. Up to 20% of pateints require treatment intensification to an advanced therapy
#AIBD2024 @IBDConference
Looking forward to presenting on April 1st about transition from peds to adult GI care for people with IBD! Hope to see you there @CCYANetwork@CCfdnNewEngland @PediatricIBD #GITwitter#IBD
There is still time to register for MyIBD Learning Patient & Caregiver Education Conference on April 1st. We have an excellent line up of presentations. Tickets are $10 and scholarships are available!
View all of the details here: https://t.co/jYce1UPItE
Our Meta‐analysis is out on @APandT The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease https://t.co/bmmIV4nPBJ - proactive TDM showing significant benefits! @Jonathansegal85 @Dr_Dee_Kumar @GastroMJB@JonnyBlackwell
📣 Calling all future #IBD fellows!
🍁 Check out our new article in the FALL issue of #ACGMagazine@AmCollegeGastro
Big thank you to our incredible faculty and fellows for their insightful, entertaining and inspiring advice! #BOOM 🔥🫶🏻🌟
⬇️ MUST DO’S for #IBD fellowship! 1/
In this article, @IBD_Houston examines safety data on ustekinumab in 🤰. In this cohort of 39 #IBD pregnancies:
🚫 no specific safety concerns with maternal ustekinumab
🚫no congenital anomalies were reported in newborns
https://t.co/zwRgPiNCeL
Results from PAPooSE group on 82 pregnancies among 77 IBD stoma pts. These are high risk pts needing MFM monitoring. @MySMFM@ColorectalDis https://t.co/pSm1ywHyqU
-->73% C section (24% emergent)
-->24% stoma complication
-->7.5% postpartum hemorrhage
--> 3/77 had bladder injury
Congratulations to our 13 #BIDMCGI graduates of the Class of 2022! We are so proud of all you have accomplished - in clinic, in endoscopy, through your research, education, & more - you are clinicians of the highest order and we can’t wait to see what you will accomplish next! 🌟